1. High Prevalence of Multidrug-resistant Organisms: MRSA, VRE, CRE, ESBLs, and C. difficile at a Chicago LTACH. (4th October 2017) Authors: Barza, Ruby; Wyant, Kodi; Patel, Parul; Patel, Jignesh; Mendoza, Katherine; Mangold, Kathy; Chavez, Natali; Kim, Kihe; Hines, David; Singh, Kamaljit Journal: Open forum infectious diseases Issue: Volume 4(2017)Supplement 1 Page Start: S160 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol‐containing oral contraceptive in healthy adult women. (14th February 2017) Authors: Trezza, Christine; Ford, Susan L.; Gould, Elizabeth; Lou, Yu; Huang, Chuyun; Ritter, James M.; Buchanan, Ann M.; Spreen, William; Patel, Parul Journal: British journal of clinical pharmacology Issue: Volume 83:Number 7(2017) Page Start: 1499 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Issue 10101 (23rd September 2017) Authors: Margolis, David A; Gonzalez-Garcia, Juan; Stellbrink, Hans-Jürgen; Eron, Joseph J; Yazdanpanah, Yazdan; Podzamczer, Daniel; Lutz, Thomas; Angel, Jonathan B; Richmond, Gary J; Clotet, Bonaventura; Gutierrez, Felix; Sloan, Louis; Clair, Marty St; Murray, Miranda; Ford, Susan L; Mrus, Joseph; Patel,... Journal: Lancet Issue: Volume 390:Issue 10101(2017) Page Start: 1499 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Pharmacokinetics of Cabotegravir in Subjects with Moderate Hepatic Impairment. (4th October 2017) Authors: Shaik, Jafar Sadik; Ford, Susan; Lou, Yu; Zhang, Zhiping; Bakshi, Kalpana; Tenorio, Allan; Trezza, Christine; Spreen, William; Patel, Parul Journal: Open forum infectious diseases Issue: Volume 4(2017)Supplement 1 Page Start: S429 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Pharmacokinetics of Cabotegravir in Subjects with Severe Renal Impairment. (4th October 2017) Authors: Parasrampuria, Ridhi; Ford, Susan; Lou, Yu; Fu, Caifeng; Bakshi, Kalpana; Tenorio, Allan; Trezza, Christine; Spreen, William; Patel, Parul Journal: Open forum infectious diseases Issue: Volume 4(2017)Supplement 1 Page Start: S429 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Population pharmacokinetics of the MEK inhibitor selumetinib and its active N‐desmethyl metabolite: data from 10 phase I trials. (22nd September 2017) Authors: Patel, Parul; Howgate, Eleanor; Martin, Paul; Carlile, David J.; Aarons, Leon; Zhou, Diansong Journal: British journal of clinical pharmacology Issue: Volume 84:Number 1(2018:Jul.) Page Start: 52 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Issue 8 (August 2017) Authors: Markowitz, Martin; Frank, Ian; Grant, Robert M; Mayer, Kenneth H; Elion, Richard; Goldstein, Deborah; Fisher, Chester; Sobieszczyk, Magdalena E; Gallant, Joel E; Van Tieu, Hong; Weinberg, Winkler; Margolis, David A; Hudson, Krischan J; Stancil, Britt S; Ford, Susan L; Patel, Parul; Gould, Elizabe... Journal: Lancet Issue: Volume 4:Issue 8(2017) Page Start: e331 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗